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Abstract
Background: Although appetite suppressants have been implicated in the development of valvular
heart disease, the exact level of risk is still uncertain. Initial studies suggested that as many as 1 in
3 exposed patients were affected, but subsequent research has yielded substantially different
figures. Our objective was to systematically assess the risk of valvular heart disease with appetite
suppressants.
Methods: We accepted studies involving obese patients treated with any of the following appetite
suppressants: fenfluramine, dexfenfluramine, and phentermine. Three types of studies were
reviewed: controlled and uncontrolled observational studies, and randomized controlled trials.
Outcomes of interest were echocardiographically detectable aortic regurgitation of mild or greater
severity, or mitral regurgitation of moderate or greater severity.
Results: Of the 1279 patients evaluated in seven uncontrolled cohort studies, 236 (18%) and 60
(5%) were found to have aortic and mitral regurgitation, respectively. Pooled data from six
controlled cohort studies yielded, for aortic regurgitation, a relative risk ratio of 2.32 (95%
confidence intervals 1.79 to 3.01, p < 0.00001) and an attributable rate of 4.9%, and for mitral
regurgitation, a relative risk ratio of 1.55 (95% confidence intervals 1.06 to 2.25, p = 0.02) with an
attributable rate of 1.0%. Only one case of valvular heart disease was detected in 57 randomized
controlled trials, but this was judged unrelated to drug therapy.
Conclusions:  The risk of valvular heart disease is significantly increased by the appetite
suppressants reviewed here. Nevertheless, when considering all the evidence, valvulopathy is much
less common than suggested by the initial, less methodologically rigorous studies.
Background
The first case reports that suggested a link between the use
of appetite suppressants and valvular heart disease were
published in 1997.[1] These initial reports were followed
by a US Food and Drug Administration (FDA) echocardi-
ographic survey, which found valvulopathy in 32.8% of
284 subjects who had been taking appetite suppres-
sants.[2] Since then, other researchers have performed
similar echocardiographic studies, some of which have in-
cluded control obese patients unexposed to appetite sup-
pressants. The rate of valvulopathy in these later studies
appears to be considerably lower than that of the original
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FDA survey, and there is now debate as to the exact risk.[3]
In view of this uncertainty, we decided to perform a sys-
tematic review of the published evidence.
Methods
The review was conducted according to a defined proto-
col.
Data sources
We used a sensitive search string for the following elec-
tronic databases:
MEDLINE 1966-September 2001 – [phentermine or fen-
fluramine or dexfenfluramine] and [(stud* or trial*) or
(valv* or aortic or mitral) or (case-control-studies or co-
hort-studies or {clinical-trial in pt}) or (phentermine/ad-
verse-effects or fenfluramine/adverse-effects or
dexfenfluramine/adverse-effects)] and [human in tg].
EMBASE 1980-Septemebr 2001 – [phentermine or fenflu-
ramine or dexfenfluramine] and [(stud* or trial*) or
(valv* or aortic or mitral) or ({case-control-study or co-
hort-analysis or clinical-trial} in der) or (phentermine/ad-
verse-drug-reaction or fenfluramine/adverse-drug-
reaction or dexfenfluramine/adverse-drug-reaction)] and
[human in der].
The search was performed independently by each of the
authors. Relevant studies were identified through a com-
bination of electronic searching and manual checking of
reference lists from previous review papers. We applied no
language restrictions.
Study selection
Studies: The following types were examined:
1) randomized, controlled trials with placebo or no treat-
ment control groups.
2) observational studies evaluating the risk of valvulopa-
thy.
Reports were included if they were full journal publica-
tions; we excluded abstracts, letters, review articles and
case reports. We contacted authors when specific aspects
of the published data required clarification.
Participants: We included studies that involved adult,
obese patients treated with appetite suppressants. In order
to maximize the likelihood of detecting adverse events, we
only accepted studies that involved at least 10 partici-
pants.
Intervention: The appetite suppressants of interest were
dexfenfluramine, fenfluramine and phentermine. We ac-
cepted studies where any of the three agents were used,
alone or in combination, for at least one month. Crosso-
ver studies were excluded.
Outcome Measures: The events of interest were echocardi-
ographically detectable aortic and mitral regurgitation.
We looked specifically for reports of valvulopathy that
met FDA case definitions, i.e. aortic regurgitation of mild
or greater severity (FDA AR), or mitral regurgitation of
moderate or greater severity (FDA MR).
Data extraction
Appraisal of Study Quality and Data Abstraction: We did
not anonymize the reports before assessment. All poten-
tially relevant studies were checked independently by the
reviewers, using a predetermined protocol, to determine
eligibility for inclusion and to extract data. A list of studies
that were excluded is available from the authors.
We recorded the numbers and severity of any valvular le-
sions. We also sought information on participants, blind-
ing, type of control, drug exposure, nature of follow-up,
and methods or criteria used in diagnosing valvulopathy.
Components of quality assessment for the randomized
controlled trials were concealment of allocation sequence,
blinding, and reporting of withdrawals. For the observa-
tional studies, we evaluated the methods of patient selec-
tion and blinding of outcome assessors.
Any discrepancies were resolved by discussion.
Data synthesis
The numbers of patients with valvulopathy in the uncon-
trolled studies were simply added up to calculate the over-
all rate from the total number of patients who underwent
echocardiography.
For the controlled studies, pooled relative risk ratios and
heterogeneity were analysed using RevMan 4.1. We used
the fixed effects model in calculating the pooled relative
risk ratios. The number needed to harm (NNH), with 95%
confidence intervals (95% CI), was calculated by applying
the calculated relative risk ratio to the pooled control
event rate.
Results
The search strategy yielded 2400 hits in total. On checking
the electronic records, 1729 clearly failed to satisfy one or
more of the inclusion criteria, leaving 671 potentially rel-
evant papers for more detailed evaluation. From these, we
accepted 57 randomized controlled trials and 14 observa-
tional echocardiographic studies. Principal reasons for ex-
clusion were: review article, case report, drug not used in
management of obese participants, clinical trial not rand-
omized or controlled, echocardiographic grade of valvu-BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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lopathy not reported in observational study. We did not
find any case-control studies that evaluated the link be-
tween valvulopathy and appetite suppressants.
We identified 57 randomized controlled trials, involving
over 5100 participants, that fulfilled our criteria. The main
features of the trials are summarized in Table 1 (details of
individual trials are available from the authors). Cardiac
echocardiography was not routinely performed in any of
the trials, although monitoring of adverse events was spe-
cifically mentioned in 47 trials. Only one case of valvular
heart disease was noted among the 41 trials that reported
adverse effects. The patient had mitral regurgitation which
was judged to be due to myocardial infarction rather than
drug therapy.
There were seven uncontrolled echocardiographic surveys
available for analysis (Table 2). [2,4–9] Overall, a total of
236 cases (18%) with FDA AR, and 58 (5%) with FDA MR
were detected in the 1279 patients evaluated. There were
considerable differences in the design of these seven stud-
ies, with particular regard to patient selection and blind-
ing of the outcome assessors. This may have accounted for
the variation in the number of cases detected – for exam-
ple, FDA AR rates ranged from 6% to 29%. Nevertheless,
these figures suggest that more than 1 in 5 patients taking
appetite suppressants were at risk of developing valvulop-
athy.
We found seven controlled echocardiographic studies that
evaluated the risk of valvulopathy in 5200 obese individ-
uals (Table 3).[10–16] Most of the participants were mid-
dle-aged women. Overall, FDA AR was found in 9.7% of
those taking appetite suppressants, and in 3.5% of con-
trols (Figure 1). The pooled relative risk ratio for FDA AR
was 2.82 (95% CI 2.20 to 3.61, p < 0.00001) with a
number needed to harm of 16 (95% CI 11 to 24). Data on
severe aortic regurgitation was reported in six studies, with
a pooled rate of 7/3045 (0.23%) in the exposed group and
4/1825 (0.22%) in the control group.
There was significant heterogeneity in the analysis of FDA
AR (χ 2 16.0, p = 0.01). As seen from the Forrest plot (Fig-
ure 1), this was accounted for by Khan's study [13] in
which the relative risk for FDA AR was 17.0, a figure which
is several times above that obtained from the other stud-
ies. When Khan's study was excluded from the meta-anal-
ysis, there was no evidence of significant heterogeneity. In
this revised analysis (Figure 2), the relative risk for FDA AR
was 2.32 (95% CI 1.79 to 3.01, p < 0.00001), with a
number needed to harm of 20 (95% CI 13 to 33).
FDA MR was much less common than FDA AR; it was
found in 2.9% of those exposed to appetite suppressants
and in 1.9% of controls (Figure 3). The pooled relative
risk ratio for FDA MR was 1.55 (95% CI 1.06 to 2.25, p =
0.02) with a number needed to harm of 99 (95% CI 44 to
909). There was no evidence of significant heterogeneity.
The effects of variables such as duration of treatment and
specific drugs on the risk of valvulopathy, was not consist-
ently reported. Only two of the seven controlled studies
evaluated the relationship between duration and valvu-
lopathy – one study found a definite correlation, while the
other did not. The remaining five controlled studies did
not comment on dose or duration. Similarly, of the seven
uncontrolled studies, three suggested that the risk of val-
vulopathy was linked to dose and/or duration, while two
studies reported exactly the opposite. Owing to the small
number of available studies and the lack of individual pa-
tient data, we believe that it would not be methodologi-
cally sound to draw any conclusions from subgroup
analysis of dose, duration or type of drug therapy.
Discussion
In this systematic overview, we present evidence from
three different types of study on the link between appetite
suppressants and valvular heart disease. Uncontrolled
Table 1: Summary of characteristics of the randomized control-
led trials analysed
Trials No. of trials
- Placebo controlled 52
- No treatment controls 5
Blinding
- Single blind 2
- Double blind 46
Drugs used and dosage
Dexfenfluramine 10–80 mg/day (mostly 
30 mg)
35
Phentermine 30 mg/day 7
Fenfluramine 40–160 mg/day 11
Phentermine-fenfluramine 30–60 mg/day 4
Mean duration 17 weeks
Range 4–60 weeks
Information on Adverse effects
Monitored for any adverse effects 47
Gave details of adverse effects 41
No details of any adverse effects 15
Patients No.
- Treated 2907
- Control 2252
- Mean age 43
- Sex 77% female
Cases of valvular heart disease
Treated 1 (but judged unrelated 
to treatment)
Controls 0BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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echocardiographic surveys yield high rates of valvulopa-
thy with over 20% of patients affected. However, control-
led echocardiographic studies show that the attributable
rate of valvular heart disease is actually much lower, at less
than 6%. No cases of valvulopathy attributable to the
drugs were reported in published randomized, controlled
trials of appetite suppressants. These differences in the
findings are intriguing and merit further discussion.
There are several methodological issues that lead us to
question the relatively high rates of valvulopathy found in
uncontrolled echocardiographic studies. These studies are
at particular risk of detection bias owing to the difficulties
in concealing the nature of the study from the outcome as-
sessors (although two studies did attempt to use blinded
readers [7,9]). The following factors appear to contribute
to the detection of high rates of valvulopathy.[3,17]
Echocardiographers aware of the possible link between
valvulopathy and appetite suppressant use may have per-
severed in searching for, or highlighting, specific valvular
lesions when performing and reviewing the scans. Simi-
larly, such subconscious preconceived notions may have
led to bias when interpreting semi-quantitative guidelines
– for example, in an obese patient, regurgitation of mild
to moderate severity could have been subconsciously clas-
sified as moderate in severity. Finally, echocardiographers
may have specifically set the technical parameters of the
machine to highlight the size and penetration of regur-
gitant jets.
The design of the uncontrolled studies, with particular re-
gard to case selection, may have undermined the value of
the findings. We could not be confident, given the design
of the seven uncontrolled studies, that that the patients
evaluated were in any way representative of the exposed
population. Several methods were used to identify pa-
tients – including random samples, convenience samples,
and case note reviews of patients referred to an echocardi-
ographic centre. Biases arising from patient selection may
have led to high rates of valvulopathy – for example, those
specially referred for assessment at echocardiographic
centres may have been at particularly high risk of valvular
disease.
In contrast, the controlled studies were larger and meth-
odologically more rigorous. Most of the participants and
their controls were either part of double-blind rand-
omized controlled trials or were identified from prescrip-
Table 2: Characteristics of uncontrolled echocardiographic studies included in analysis
Author Year Patient selection Drugs used Mean 
duration 
(days)
Blinding of outcome 
assessment
Total FDA 
AR
FDA 
MR
Burger [4] 2001 343/591 participants of open-
label study via postal invitation
Combination of fenflu-
ramine-phentermine
370 Performed 
unblinded, reviewed 
on tape by two inde-
pendent readers
343 19 
(6%)
3 (1%)
FDA [2] 1997 Some convenience, some ran-
dom. Prevalence survey across 
five clinics in USA where obese 
patients were treated
Fenfluramine, dexfenflu-
ramine, and/or phentermine
Median 
420
None 284 80 
(28%)
18 
(6%)
Fisher [5] 1998 Consecutive patients with his-
tory of appetite suppressants 
referrred for echocardiography
Combination of fenflu-
ramine-phentermine
Not 
stated
None 156 29 
(19%)
4 (3%)
Kancherla 
[6]
1999 Consecutive patients with his-
tory of appetite suppressant use 
referred for echo study
Fenfluramine, dexfenflu-
ramine and/or phentermine
307 None 200 24 
(12%)
10 
(5%)
Lepor [7] 2000 Consecutive patients with his-
tory of appetite suppressant use 
referred for echocardiography
Combination of fenflu-
ramine-phentermine
321 Blinded readers with 
2nd independent 
assessment
85 24 
(28%)
9 
(11%)
Teramae 
[8]
2000 Retrospective review of patients 
referred for suspected valve dis-
ease
fenfluramine, dexfenflu-
ramine and/or phentermine
245 None 191 55 
(29%)
12 
(6%)
Wadden 
[9]
1998 20 of 26 participants in open-
label trial
Combination of fenflu-
ramine-phentermine
730 Two independent 
readers, blinded to 
clinical status
20 5 
(25%)
2 
(10%)
Total 1279 236 
(18%)
58 
(5%)BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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tion registry data. All the studies attempted to conceal the
treatment group from the outcome assessors. The impor-
tance of such blinding is amply illustrated by Khan's
study, which started off as an unblinded study but later
became a blinded controlled study.[13] Rates of valvulop-
athy were in excess of 30% in the first 67 participants eval-
uated without blinding, but fell to only 19% after
blinding of the primary reader was introduced.[3] Inter-
estingly, the control patients in Khan's study had a very
low rate of FDA AR (1.3%) compared with the controls in
other studies in which FDA AR ranged from 2.1% to
10.9%, with a mean of 3.8%. This may reflect failure of
blinding, or a difference in the selection process used in
Khan's study in which controls did not come from the
same medical centres but were recruited later through me-
dia advertisements. These methodological differences
would explain why there is heterogeneity of the data, and
justify our decision to perform the final meta-analysis for
FDA AR without Khan's study.
The relatively high rates of valvulopathy found in the un-
controlled studies may therefore be partly explained by
case selection and detection bias. However, the higher
rates of valvulopathy in uncontrolled studies (and also in
Khan's cohort) may also have been due to the longer du-
ration of drug exposure in these patients, a mean of 310
days compared with 266 days in the controlled studies.
Similarly, reversibility of the valvular lesions after cessa-
tion of treatment may explain why the uncontrolled sur-
veys, being the earliest ones, yielded the highest rates. In
contrast, some of the patients in the later controlled stud-
ies had not taken treatment for several months. Nonethe-
less, the relative rate of regression seems to be less than
10–20% per annum, and cannot completely account for
the large differences between controlled and uncontrolled
studies.[18,19]
Such differences are not surprising. Unreliable estimates
of the magnitude of treatment effects can arise from small
Table 3: Characteristics of cohort-controlled echocardiographic studies included in analysis
Author Year Patient selection Ascertainment of 
drug exposure
Mean duration (days) Blinding of outcome assess-
ment
Gardin [10] 2000 Recruited by physicians 
known to be frequent 
prescribers – 25 cen-
tres. Controls from 
same centres
Medical records 
and interview – 
dexfenfluramine, 
or combination of 
fenfluramine-phen-
termine
252 Performed blind, tapes 
read blind at central labo-
ratory
Hensrud [11] 1999 Patients from double-
blind randomized con-
trolled trial
In trial of fenflu-
ramine-phenter-
mine
284 Blinded reviewer
Jollis [12] 2000 Prescription registry 
data for 33 practices, 
controls from same 
centres
Prescription regis-
try – fenfluramine-
phentermine 
together
337 Blinded reviewer
Khan [13] 1998 Participated in drug 
study at medical cen-
tre, controls from 
media advert
Medical records 
and self-reports – 
dexfenfluramine, 
fenfluramine or 
phentermine.
615 67 unblinded; others per-
formed blind
Shively [14] 1999 Recruited by prescrib-
ers at 26 centres; con-
trols were obese 
patients at same cen-
tres with no drugs for 
5 years
Medical records – 
dexfenfluramine
207 Blinded and told not to dis-
cuss medication history
Wee [15] 1998 46/76 patients with 
previous echo from 
two academic centres; 
patients acted as their 
own controls
Medical records – 
dexfenfluramine or 
fenfluramine
Median 160 Performed unblinded; 
reread in blinded manner 
by one of two readers
Weissman [16] 1998 1072/1212 patients 
from double-blind ran-
domized controlled 
trial
In a trial of dexfen-
fluramine
71 Double blinding of trial 
maintainedBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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studies simply because of random variation.[20] Further-
more, exaggerated treatment effects are more likely to be
seen in studies with methodological weaknesses, such as
lack of blinding. [21,22] Our findings amply illustrate
this. Although decisions on drug safety have often de-
pended on case reports and uncontrolled observations,
[23] our results suggest that there can be significant prob-
lems in using such data. There is a definite danger that
useful drugs may be cast aside prematurely following
"knee-jerk" reactions to safety scares founded on poor ev-
idence. We strongly believe that there should be far greater
emphasis on using methodologically rigorous studies to
generate more precise safety data.
Although systematic echocardiographic assessments were
not carried out in the trials, we can still draw useful con-
Figure 1
Relative risks for FDA AR with appetite suppressants.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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clusions from the data. The absence of any clinically diag-
nosed cases of valvular heart disease in 2907 patients
treated over a mean of 17 weeks suggests that the valvu-
lopathy was not of sufficient severity to be found on rou-
tine physical examination. Any symptoms must also have
been so mild that they were not reported to, or detected
by, the investigators. Similarly, a retrospective, popula-
tion-based study showed that only 11 of 9765 patients
(0.11%) taking appetite suppressants had been diagnosed
as having valvular heart disease by their physicians.[24]
These findings indicate that echocardiographically detect-
able valvulopathy is often subclinical and may not lead to
serious sequelae.[25]
Nonetheless, one cannot help but feel that this debacle
could have been avoided altogether if physicians and re-
Figure 2
Relative risks for FDA AR with appetite suppressants after exclusion of Khan's study.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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searchers had shown more care. Why wasn't routine
echocardiography part of the safety monitoring protocols
in the clinical trials, when there had been so much contro-
versy in the past with pulmonary hypertension and appe-
tite suppressants? [26] Furthermore, in view of the lack of
comprehensive safety data, prescribers of appetite sup-
pressants should perhaps have attempted to limit the
treatment duration (as advised by the regulatory authori-
ties) and avoided the use of unlicensed drug combina-
tions. Although it would be far simpler to lay all the blame
on the drug itself, there are clearly important lessons here
for those involved in evaluating, or prescribing potentially
harmful drugs.
Although the risks faced by individual patients (number
needed to harm for FDA AR of 20) are much lower than
Figure 3
Relative risks for FDA MR with appetite suppressants.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/6
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originally suggested, it is worth bearing in mind that the
drugs could have caused valvulopathy in hundreds of
thousands of the six million Americans prescribed the
drugs in 1996.[3] Even if severe valvulopathy developed
in only a small proportion of those affected, there would
still be hundreds of people experiencing serious clinical
sequelae.
There are some limitations to this systematic review. We
used strict criteria and FDA case-definitions in selecting
the studies, and only a limited number were found to be
suitable for inclusion in the final analysis. Furthermore,
our findings are based on aggregate data from published
studies, and we did not have access to individual patient
data. We were therefore unable to analyse in detail the ef-
fects of variables such as treatment duration, dose, type of
drug, and interval between the end of therapy and
echocardiography. For example, differences in the rate of
valvulopathy among the studies may have been partly ac-
counted for by differences in duration of treatment in the
study cohorts. Similarly, exposure to combination thera-
py, such as the commonly used "phentermine-fenflu-
ramine" combination, may well carry a much higher risk
than exposure to phentermine alone. The effects of multi-
ple variables cannot be properly appraised without indi-
vidual patient data, and are therefore not within the scope
of this systematic review.
A final word of warning. Despite withdrawal by the regu-
latory authorities, sizeable numbers of people may still be
consuming these appetite suppressants from other sourc-
es such as an unlicensed prescription, or from Chinese
herbal preparations.[27,28] As such, the safety informa-
tion from our analysis continues to be relevant, both to
slimmers who are still trying for a cure, and to medical
practitioners who may become involved in their care.
Conclusions
Patients treated with appetite suppressants are at signifi-
cantly increased risk of developing valvular heart disease.
However, the risk of valvulopathy found in this systematic
review is much lower than that suggested by initial, less
methodologically rigorous studies. We strongly believe
that judgements on drug safety should be backed by evi-
dence from high quality sources.
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